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Kaposi’s sarcoma (KS) in HIV-infected individuals can have a wide range of clinical outcomes, from indolent skin tumors to a
life-threatening visceral cancer. KS tumors contain endothelial-related cells and inflammatory cells that may be HIV-infected. In
this study we tested if HIV evolutionary patterns distinguish KS tumor relatedness and progression. Multisite autopsies from
participants who died from HIV-AIDS with KS prior to the availability of antiretroviral therapy were identified at the AIDS
and Cancer Specimen Resource (ACSR). Two patients (KS1 and KS2) died predominantly from non-KS-associated disease and
KS3 died due to aggressive and metastatic KS within one month of diagnosis. Skin and visceral tumor and nontumor autopsy
tissues were obtained (𝑛 = 12). Single genome sequencing was used to amplify HIV RNA and DNA, which was present in all
tumors. Independent HIV tumor clades in phylogenies differentiated KS1 and KS2 from KS3, whose sequences were interrelated
by both phylogeny and selection. HIV compartmentalization was confirmed in KS1 and KS2 tumors; however, in KS3, no
compartmentalizationwas observed among sampled tissues.While the sample size is small, theHIV evolutionary patterns observed
in all patients suggest an interplay between tumor cells and HIV-infected cells which provides a selective advantage and could
promote KS progression.
1. Introduction
Prior to the human immunodeficiency virus (HIV) epidemic,
Kaposi’s sarcoma (KS) was considered a very rare disease,
found primarily in Mediterranean countries and in organ
transplant recipients [1]. Although Human Herpes Virus 8
(HHV8) is the etiological cause of KS [2], most HHV8+
individuals do not develop KS. Early in theHIV epidemic, KS
was so frequently diagnosed that it was considered an AIDS-
defining illness [3–5]. Prior to the mid-1990s and the use of
combined antiretroviral therapy (cART), HIV+ patients had
a 40% lifetime risk of developing KS [6]. Although combined
antiretroviral therapy (cART) has undeniably reduced KS-
associated mortality among HIV-infected patients [7–9], the
statistical impact is unclear due to differing clinical defini-
tions and cART adherence problems [10, 11]. Furthermore,
KS is still one of the most common cancers among HIV+
patients [12] despite cART-improved CD4+ T-cell counts,
low viral loads, and reduced risk of opportunistic infections
[13–16]. KS is particularly problematic in resource-poor
settings where cART and chemotherapy are limited [6, 17–
19]; however, even in resource-rich settings, full remission of
KS using cART and chemotherapy occurs in less than 50% of
HIV+ patients with disseminated disease [20].
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KS lesions can be solitary, localized, or disseminated,
but the relationship among tumors in a single individual
is largely unknown. While many KS lesions are cutaneous
and indolent, tumors can occur in the oral cavity, lymph
nodes, and viscera, which can result in fatal complica-
tions due to interference with normal body function. The
growth of lesions can be very slow or explosively fast.
The KS defining cell-type is a spindle cell (SC) [21, 22]
that expresses markers of both endothelial and macrophage
lineages [23]. KS tumors are polyclonal, positive for the
presence of HHV8 virus, which infects the tumor-associated
B-cells and SCs [23], and highly vascularized, giving them
a distinguishing purple color. Inflammatory lymphocytes
and monocytes/macrophages populate and enrich the KS
tumor environment for tumor growth through production
of a variety of cytokines [23]. These immune cells are all
potential targets for HIV; however, to our knowledge, only
one study assessed KS tumors for the presence of HIV using
an early hybridization technique [24]. SCs can be cultured
from PBMCs of patients with KS, suggesting that circulating
SCs may lead to the appearance of multiple KS lesions [23].
HIV has the potential to infect and evolve in many
anatomical tissues, including tumors [25–27]. Previously,
we showed that the viral populations in lymphoma tumors
were distinct from HIV in healthy tissues [25]. Here, our
goal was to characterize HIV populations in KS tumors to
determine whether HIV evolution could be used to track
tumor relatedness and progression in native KS uncompli-
cated by the use of cART. We obtained tumor and nontumor
tissues sampled post mortem from the AIDS and Cancer
Specimen Resource (ACSR) from three HIV+/KS+ patients
who died from aggressive AIDS, and we generated HIV
env-nef sequences using single genome sequencing (SGS) to
characterize viral evolutionary patterns.
2. Materials and Methods
2.1. Patients and Biomaterial. The three male patients
included in this studywere diagnosedwithHIV infection and
died with advanced AIDS without receiving cART (Table 1).
100mg of frozen autopsy tumor and nontumor tissues was
obtained through the ACSR (http://acsr.ucsf.edu/). Tissues
were classified as tumor or nontumor by histological exam-
ination. The ACSR is a National Cancer Institute-funded
tissue-banking program that obtains tissues from patients
after appropriate consent and releases tissues to investigators
following approval of the proposed study and deidentification
of samples and clinical histories. The ACSR is recognized by
theOffice of Biorepositories and BiospecimenResearch at the
National Institutes of Health as being HIPAA compliant and
in accordance with the ethical standards of the Declaration
of Helsinki. Additionally, all material was obtained under
approval from the University of California at San Francisco
Committee on Human Research.
2.2. RNA/DNA Extractions. Total RNA and genomic DNA
were isolated separately from each tissue section (30–50 ng)
using AllPrep DNA/RNAMini Kit (Qiagen #80204). Tissues
were homogenized just prior to extraction in Buffer RLT Plus
(lysis buffer) using a TissueRupter rotor-stator homogenizer
(Qiagen #9001271) with a fresh sterile disposable probe
(Qiagen #990890) for each sample.Manufacturer’s guidelines
were followed, with the exception of two 50 𝜇L final elutions
using RNase-free water during the RNA isolation.The 100 𝜇L
final volume of RNA generated was concentrated using
RNeasyMinElute Cleanup Kit (Qiagen #74204). RNA and
DNA extractions, cDNA synthesis, and first-round PCR
setup were conducted in a restricted-access, amplicon-free
room with separate air handling and laboratory equipment
where no amplified PCR products or recombinant cloned
plasmids were allowed, and work surfaces and equipment
were thoroughly cleaned before and after use with Eliminase
(Decon Labs, Inc.). cDNA was synthesized using Super-
Script III First-Strand Synthesis System (Invitrogen Life
Technologies #18080-051) using the provided Oligo(dT)
20
primer according to manufacturer’s recommendations. RNA
was incubated at 65∘C for 5 minutes with deoxynucleoside
triphosphates (0.5mM) and 5 𝜇M Oligo(dT)
20
and then
cooled quickly to 4∘C. First-Strand cDNA Synthesis was
performed in a 40 𝜇L reaction volume containing 1x reverse
transcription buffer (10mM Tris-HCl [pH 8.4], 25mMKCl),
5mMMgCl
2
, 10mM dithiothreitol, 2 U/𝜇L of RNase-OUT
(RNase inhibitor), and 10U/𝜇L SuperScript III RT. The
reaction was heated to 50∘C for 50 minutes, followed by
85∘C for 5 minutes. The reaction was cooled to 37∘C and
0.1 U/𝜇L of E. coli RNase H was added, followed by a 20-
minute incubation. cDNA was stored at −20∘C.
2.3. Sequencing Protocol. Amodified single genome sequenc-
ing protocol was used to amplify linked HIV env and
nef sequences [28]. cDNA and genomic DNA were seri-
ally diluted until an average of 30% or less of the nested
PCR reactions were positive. During the first-round PCR,
diluted cDNA or genomic DNA was amplified in 25𝜇L
reactions containing 1x Platinum Blue PCR SuperMix
(Invitrogen Life Technologies) and 0.2 𝜇M of each primer:
EF2, 5󸀠-ACAGTCTATTATGGGGTRCC-3󸀠 and NR1, 5󸀠-
AGCTCCCAGGCTCAGATCT-3󸀠 (6333–6352 bp and 9558–
9576 bp of HIV HXB2, resp.) with the following cycling
parameters: initial denaturation 95∘C for 5 minutes, followed
by 35 cycles of denaturing at 94∘C for 1 minute, annealing at
58∘C for 1 minute, and extension at 72∘C for 4minutes, with a
final extension time of 10 minutes at 72∘C. A second round of
gp120 PCR consisted of 1𝜇L of the first-round PCR added to
a 24𝜇L second-round reaction consisting of 1x PlatinumBlue
PCR SuperMix (Invitrogen Life Technologies) and 0.2 𝜇M
of each primer: EF3, 5󸀠 CATAATGTTTGGGCCACACA-
3󸀠 and ER2, 5󸀠-CACCACTCTTCTYTTTGCC-3󸀠 (6420–
6439 bp and 7724–7742 bp of HIV HXB2, resp.) with the
following cycling parameters: initial denaturation 95∘C for 5
minutes, followed by 35 cycles of denaturation at 94∘C for
1 minute, annealing at 58∘C for 1 minute, and extension at
72∘C for 2 minutes, with a final extension time of 10 minutes
at 72∘C. This second-round PCR generated a 1.3 Kb product,
nearly covering the entire env gp120 gene. Second-round
env gp120 PCR products were visualized on 1% agarose gels
stained with ethidium bromide, and reactions containing a
single 1.3 Kb product were considered positive and selected
Sarcoma 3
Ta
bl
e
1:
Pa
tie
nt
cli
ni
ca
lh
ist
or
y.
Pa
tie
nt
A
ge
1
M
aj
or
co
m
or
bi
di
tie
s2
KS
lo
ca
tio
n
Ti
m
es
in
ce
KS
di
ag
no
sis
(m
on
th
s)
Le
ng
th
of
H
IV
in
fe
ct
io
n
(y
ea
rs
)
A
na
to
m
ic
al
lo
ca
tio
n
of
bi
op
sy
C
on
ce
nt
ra
tio
n
(n
g/
𝜇
L)
N
um
be
ro
fe
nv
se
qu
en
ce
s
N
um
be
ro
fn
ef
se
qu
en
ce
s
RN
A
D
N
A
RN
A
D
N
A
RN
A
D
N
A
KS
1
34
Ly
m
ph
om
a,
M
AC
,
PC
P,
cy
to
m
eg
al
ov
iru
s
Sk
in
,p
le
ur
a,
lu
ng
s,
tr
ac
he
a,
ly
m
ph
no
de
,l
iv
er
,
ad
re
na
lg
la
nd
s
U
nk
no
w
n
7
KS
sk
in
14
4
15
4
22
8
24
9
KS
ly
m
ph
no
de
16
8
27
6
13
21
14
21
Ly
m
ph
no
de
12
0
12
.1
37
22
35
26
Ki
dn
ey
>
20
0
8.
18
5
0
9
0
KS
2
31
BC
BL
Sk
in
,p
le
ur
a,
lu
ng
s,
es
op
ha
gu
s,
sm
al
lb
ow
el
∼
5
U
nk
no
w
n
KS
sk
in
16
5
44
14
10
18
12
KS
sm
al
lb
ow
el
19
2
9.8
4
4
0
5
0
Li
ve
r
19
1
8.
42
0
0
0
0
Sp
le
en
19
0
13
.9
23
1
31
2
KS
3
28
A
gg
re
ss
iv
eK
S
Sk
in
,p
le
ur
a,
lu
ng
s,
tr
ac
he
a,
es
op
ha
gu
s,
sm
al
l
bo
w
el,
co
lo
n,
re
ct
um
,i
lia
cl
ym
ph
no
de
s,
m
es
en
te
ric
ly
m
ph
no
de
s,
pa
ra
-a
or
tic
ly
m
ph
no
de
s,
pa
ra
tr
ac
he
al
ly
m
ph
no
de
s
∼
1
9
KS
sk
in
49
51
6
2
2
6
KS
sm
al
lb
ow
el
16
4
39
.4
16
25
14
24
Li
ve
r
16
1
33
.4
14
5
15
5
St
om
ac
h
78
.2
40
.2
24
8
20
8
1
A
ge
in
ye
ar
s;
2
M
AC
:M
yc
ob
ac
te
riu
m
av
iu
m
co
m
pl
ex
;P
CP
:P
ne
um
oc
ys
tis
pn
eu
m
on
ia
;B
CB
L:
bo
dy
ca
vi
ty
ba
se
d
ly
m
ph
om
a.
4 Sarcoma
for sequencing. Subsequently, the first-round reactions that
corresponded to positive second-round gp120 PCRs were
then used to amplify the nef gene sequence. Second-round
nef PCR consisted of 1 𝜇L of the first-round PCR added to a
24𝜇L second-round reaction consisting of 1x Platinum Blue
PCR SuperMix (Invitrogen Life Technologies) and 0.2 𝜇M
of each primer: NF1, 5󸀠-TTAGGCAGGGATAYTCACC-3󸀠
and NR2, 5󸀠-ATCTGAGGGCTCGCCACT-3󸀠 (8347–8365 bp
and 9488–9505 of HIV HXB2, resp.) with the following
cycling parameters: initial denaturation 95∘C for 5 min-
utes, followed by 35 cycles of denaturation at 94∘C for 1
minute, annealing at 58∘C for 1 minute, and extension at
72∘C for 2 minutes, with a final extension at 72∘C for 10
minutes. Second-round nef PCRs were visualized on 1%
agarose gels stained with ethidium bromide, and reactions
containing single 1.1 Kb products were considered positive
and selected for sequencing. The primers were designed
using Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/) and by
observing regions of conservation in alignments of published
HIV subtype B sequences downloaded fromLosAlamosHIV
Sequence Database (http://www.hiv.lanl.gov/). Sequencing
was performed on an Applied Biosystems 3730xl DNA Ana-
lyzer (Life Technologies) at the University of Florida Inter-
disciplinary Center for Biotechnology Research (UF ICBR).
All sequences were assembled and aligned with the Geneious
R7 software package (Biomatters http://www.geneious.com/)
followed by a manual optimization of regions containing
insertions and deletions. Sequence data has been submitted
to GenBank (Accession numbers KU709129–KU709831).
2.4. Sequence Analysis. Env and nef alignments were gen-
erated using ClustalW [29] in MEGA5 [30] with further
optimization performed by hand. Due to a large number
of insertions and deletions that are typically problematic to
align, regions with substantial insertions and deletions in env
V1, V2, andV4 domains were removed. An initial maximum-
likelihood phylogeny was inferred using sequences from all
patients for both genes to ensure no cross-contamination.
Pairwise distance analysis within and between RNA and
DNA tissue sequence populations over time was assessed in
MEGA5 [30] using the Tamura-Neimolecularmodel (identi-
fied usingModel-Selection) with standard error estimated by
1000 bootstrap replicates. The Kruskal-Wallis test was used
to determine significance between the mean pairwise dis-
tances in different anatomical tissues. Individual maximum-
likelihood phylogenies were inferred for each patient under a
GTR model of nucleotide evolution and gamma distributed
rate variation among sites (+G) using PhyML [31]. Statistical
support was assessed with 200 bootstrap replicates. The
Slatkin-Maddison test [32] was used to determine com-
partmentalization between sequences derived from different
tissues, and significance was assessed using 1,000 replicates
of tip randomization, implemented in HYPHY v.1.0 [33].The
fast, unconstrained Bayesian approximations for inferring
selection (FUBAR) model, implemented in Data Monkey
(http://datamonkey.org/), were used to identify amino acid
sites under selection in sequences derived from different
tissues for each individual. Sites with posterior probability
>0.9 of an increased (diversifying) or decreased (purifying)
rate of nonsynonymous relative to synonymous substitutions
were considered to have experienced a significant level of
selective pressure. Selected sites were numbered according
to the molecular HIV clone HXB2 (GenBank Accession
#AF358141).
3. Results
3.1. Clinical Characteristics of the Patient Cohort. All patients
(KS1–KS3) had CD4 counts <50 cells/mm3 at death and were
diagnosed with KS only months prior to death (Table 1).
KS1 lived with HIV infection for seven years. He was hospi-
talized due to Mycobacterium avium complex, Pneumocystis
pneumonia, and wasting syndrome eleven months prior to
death. Five months prior to death, medical notes indicate
multipleAIDS-like symptoms; however, KSwas not specified.
At autopsy, numerous infections were identified throughout
his body, including disseminated KS, which either had not
been previously reported or had originated closer to death.
KS2’s clinical history is similar to that of KS1 in having
multiple infections; however, this patient had an initial KS
diagnosis five months prior to death. Also, this patient was
diagnosed with an aggressive body cavity based lymphoma
(BCBL) four months prior to death that was treated with
chemotherapy. BCBL may be related to primary effusion
lymphoma which is typically caused by HHV8, the Kaposi
sarcoma herpes virus. KS3 had a nine-year history of HIV
infection with reoccurring upper respiratory tract infections.
He was diagnosed with KS one month prior to death. His
KS lesions became rapidly disseminated on the skin and
internally, which lead directly to his death due to respiratory
distress.
3.2. HIV RNA and DNA Was Successfully Sequenced from
All KS Tumors. Viral sequences were obtained from RNA
in 13/14 tissues and from DNA in 12/14 tissues (Table 1).
A preliminary maximum-likelihood (ML) phylogenetic tree
of all sequences confirmed a distinct population of HIV
sequences for each patient, indicating no laboratory cross-
contamination.
3.3. KS Tumors Can Contain Distinct HIV Isolates. ML phy-
logenies were inferred for env and nef sequence populations
for all three patients. In the KS1 env phylogeny, four distinct
and well-supported clades (A–D) were apparent that con-
tained the majority of tumor-derived sequences (Figure 1).
The relatively long internal branches leading to each clade
indicate considerable divergence from the rest of the viral
population. The majority of lymph node tumor sequences
(19/34) were within two distinct clades (A, D). The majority
of skin tumor sequences (20/32) were also located in two
different distinct clades (B-C). One of these (B) contained
both DNA and RNA sequences, while the other (C) was
comprised exclusively of RNA skin tumor sequences. Most
of the terminal branches leading directly to skin tumor-
derived sequences were very short, while those leading to
the lymph node tumor-derived sequences were considerably
longer and showed more branching within the clade. The
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A
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C
D
E
F
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Lymph node tumor RNA
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(a)
nef
Lymph node tumor DNA 
Lymph node tumor RNA
Skin tumor DNA 
Skin tumor RNA
Kidney RNA 
Lymph node DNA
Lymph node RNA
>85% bootstrap
A
B
C
D
E
0.01
(b)
Figure 1:Maximum-likelihood phylogenies for KS1. Phylogenies were inferred for each patient using env (a) and nef (b) sequence alignments.
Tips are labeled with symbols corresponding to the tissue of origin for each sequence. Branches with red lines indicate bootstrap values
>85/200. Branches are scaled in substitutions/site according to the scale under each tree. Clades labeled A–F are discussed in the text.
remaining lymph node and skin tumor RNA and DNA
sequences were located in highly mixed clades (E-F). The nef
phylogeny for KS1 had similar branching patterns, with even
more pronounced diversity in one lymph node tumor clade
(C). Similarly, all skin tumor-derived sequences except one
clustered together in a distinct and well-supported clade in
KS2 for both env and nef (A) (Figure 2). Small bowel tumor-
derivedRNA sequenceswere interspersedwith the nontumor
spleen-derived sequences in both genes; however, few bowel-
derived sequences were obtained (𝑛 = 9). Branches in the
nontumor clade showed considerable structure in both genes,
consistent with a continuously diversifying virus population.
In the nef phylogeny, two distinct clades were evident within
themixed clade, whichwas not present in the env tree. In con-
trast, for KS3, all tumor- and nontumor-derived sequences
were largely interspersed in both env and nef phylogenies
(Figure 3). Three well-supported clades were present in both
genes (A–C). Interestingly, this patient was diagnosed with
advanced and aggressive tumorigenesis less than one month
prior to death.
3.4. KS-Associated Virus Is Compartmentalized in Tumors
in KS1 and KS2 but Not in KS3. When pairwise distances
were calculated for sequences derived from each tumor and
nontumor tissue, only one significant differencewas observed
(𝑝 < 0.001) (KS1 lymph node tumor nef versus nontumor
nef sequences). Viral populations were significantly com-
partmentalized within each of the two tumors and normal
tissues for both env and nef in KS1 and KS2 (𝑝 < 0.001). On
the other hand, gene flow among the three sites was found
in both genes in KS3 (env: 𝑝 = 0.021; nef : 𝑝 = 0.171).
Viral populations from combined tumor locations were again
significantly compartmentalized compared with nontumor
populations in env and nef in KS1 and KS2, as well as in nef
for KS3 (𝑝 < 0.001).
3.5. Positively and Negatively Selected Codons Were Fewer and
Tissue-Specific in KS1 and KS2 in Contrast to KS3 (Tables 2
and 3). The proportion of codons under selection in env
did not significantly vary between positively and negatively
selected sites overall or within any single subject. However,
the number of positions under either selective pressure was
significantly higher in KS3 than in KS1 and KS2 (𝑝 < 0.01).
In nef, a significantly higher number of negatively selected
codons over positively selected codons were observed in all
patients (𝑝 < 0.01). Codons under selection were tissue-
specific in both KS1 and KS2, with only one being shared
between two tissues in KS2. In contrast, in KS3 env sequence
populations, all shared positively and negatively selected
codons in tumor tissues were also identifiedwithin nontumor
6 Sarcoma
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B
C
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Small bowel tumor RNA
Skin tumor DNA
Skin tumor RNA
Spleen DNA
Spleen RNA
>85% bootstrap
Small bowel tumor RNA
Skin tumor DNA
Skin tumor RNA
Spleen DNA
Spleen RNA
>85% bootstrap
nef
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C
0.01
Figure 2: Maximum-likelihood phylogenies for KS2. See legend under Figure 1.
env
A
B
C
0.01
Small bowel tumor DNA
Small bowel tumor RNA
Skin tumor DNA
Skin tumor RNA
Liver DNA
Liver RNA
Stomach DNA
Stomach RNA
>85% bootstrap
Small bowel tumor DNA
Small bowel tumor RNA
Skin tumor DNA
Skin tumor RNA
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Stomach RNA
>85% bootstrap
nef
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0.01
Figure 3: Maximum-likelihood phylogenies for KS3. See legend under Figure 1.
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Table 2: Number (and percent) of codons under positive or negative selection in tumor and nontumor sites in env sequence populations.
Patient Tissue # positivelyselected sites (%)
Codon position of shared
positively selected sites
# negatively
selected sites
Codon position of shared
negatively selected sites
KS1 (359)
Skin tumor 7 (1.9) None 7 (1.9) na
Lymph node
tumor 1 (0.3) None 7 (1.9) 122
Nontumor None None 8 (2.2) 122
KS2 (394)
Skin tumor 8 (2.0) 464 5 (1.2) 150
Small bowel
tumor None None None None
Nontumor 5 (1.2) 373 4 (1.0) 150
KS3 (373)
Skin tumor 3 (0.8) 464 6 (1.6) 207, 247
Small bowel
tumor 10 (2.6) 183, 336, 396 16 (4.2)
103, 118, 207, 228, 238, 246,
254, 276, 374, 408, 415, 445
Nontumor 11 (2.9) 143, 167, 183, 336, 454 21 (5.6) 103, 118, 207, 228, 238, 246,254, 276, 374, 408, 415, 445
Table 3: Number (and percent) of codons under positive or negative selection in tumor and nontumor sites in nef sequence populations.
Patient Tissue # positivelyselected sites
Codon position of shared
positively selected sites
# negatively
selected sites
Codon position of shared
negatively selected sites
KS1 (207)
Skin tumor 0 None 3 (1.5) 188
Lymph node
tumor 4 (1.9) None 18 (8.7) 8, 37, 188
Nontumor 1 (0.5) None 4 (1.9) 8, 37, 188
KS2 (205)
Skin tumor 1 (0.5) 190 0 None
Small bowel
tumor 1 (0.5) 190 4 (2.0) 81
Nontumor 2 (1.0) 190 5 (2.4) 81
KS3 (207)
Skin tumor 1 (0.5) None 7 (3.4) 30, 65, 147, 151, 191, 195
Small bowel
tumor 1 (0.5) None 14 (6.8)
4, 30, 63, 65, 111, 129, 151,
164, 191, 195
Nontumor 1 (0.5) None 21 (10.1) 4, 63, 111, 129, 147, 151, 164,191, 195
sequences; similarly, in KS3 nef sequence populations, all
shared selected codons from tumors were identified in
nontumor tissues except codon positions 31 and 67.
4. Discussion
In this study we examined if HIV evolutionary patterns could
differentiate metastatic KS in patients untreated with cART.
We analyzed HIV env and nef sequences from tumor and
nontumor anatomical sites from three subjects who died with
KS.Medical records indicated that subjects KS1 andKS2 had a
slower KS progression than subject KS3; however, all patients
had visceral KS, indicating an advanced cancer at death
from AIDS. HIV RNA and/or DNA was amplified from all
tumors in the study, demonstrating that, similar to a previous
study [25], cancer tissues contain substantial amounts ofHIV.
Furthermore, HIV sequence populations from most tissues
had similar genetic distances, indicating no constraints to
HIV evolution in any of the tissue environments examined.
HIV from tumor sites in KS1 and KS2 was compart-
mentalized relative to the nontumor virus, with limited gene
flow between compartments; however, subpopulations of
virus were also present within tumors. Additionally, codon
selection analysis demonstrated that, at the protein level, KS1
and KS2 had sequence populations evolving under indepen-
dent selective pressures in different tumor/nontumor sites.
In contrast, the patient who died from highly aggressive KS
(KS3) showed remarkably different patterns. Here the virus
in tumor and nontumor tissue was completely interspersed
with a non-tissue-specific viral population structure. These
findings could result from a number of scenarios, including
the following: (1) subpopulations of virus in tumor could
result from recent viral migration from another, unsampled
anatomical location; (2) the viral population in the tumors is
evolving independently due to a physical barrier restricting
gene flow; (3) the viral populations in the tumors are evolving
in response to local selective pressures; (4) viral sequences
in one or more sites could represent archival virus that was
8 Sarcoma
reactivated because of the cancer growth. The first scenario
is untestable here; however, we are conducting additional
studies withmore tumor and nontumor tissues fromotherKS
patients, including KS derived from patients on cART with
no detectable plasma viral load. While the second scenario
is possible, unlike the brain in which viral flow is impeded
by the blood-brain barrier, KS tumors are highly vascular-
ized which would in theory provide ample opportunity for
migration. Furthermore, a small number of tumor viruses
were found in nontumor tissues, also suggesting a lack of
physical barrier. In considering the third and fourth scenario,
we did find that codon positions were under varied selective
pressures in the tumors fromKS1 and KS2 when compared to
nontumor tissues (as expected from the phylogeny). For KS3,
most, but not all, selected codons were shared among tissues;
however, this patient had widely metastatic KS at the time of
death.Therefore, it is possible that tumor-compartmentalized
HIV populations could have existed in this patient prior
to the rapid outgrowth and spread of the cancer, perhaps
represented by one of the distinct subpopulations.
Reactivation and clonal expansion of viral populations
could be consistent with the large clades of identical or nearly
identical tumor-associated virus in KS1 and KS2 phylogenies
and with the separation of DNA and RNA derived sequences
into different clades within tumors of KS1. This hypothesis
could be investigated further by identifying the infected
cells types within each tumor. Furthermore, identifying the
insertion sites within the host genome in these tumors could
help understand if HIV-infected cells in tumors are physically
migrating to other tumor sites. A recent HIV integration site
study showed that one mechanism of HIV persistence within
T-cells is related to clonal expansion [34]. Interestingly, the
authors also found that insertion sites were enriched for genes
involved in cell growth [34], suggesting that the insertion
sites themselves may promote tumorigenesis. Studies within
cancer and AIDS dementia tissue macrophages performed in
our lab showed that major HIV integration sites in tissue-
associated macrophages (TAMs) were related to cellular acti-
vation including those just upstream of the c-fes oncogene,
which could contribute to clonal expansion [35–38]. This is
consistent with a sequential pathogenesis model in which
the insertion site of the virus promotes persistent cellular
activation, clonal expansion, andmigration of HIV+ from the
tumor to nontumor sites [36].
The patients studied here were all cART-naı¨ve; however,
KS remains a substantial comorbidity even for patients
undergoing cART. For some patients, rapid progression of KS
occurs under cART even with an undetectable viral load [39].
These cases are frequently classified as related to immune
reconstitution inflammatory syndrome (IRIS) [19, 39, 40],
a well-studied phenomenon of resurgence of underlying
pathologies during cART [41–46]. IRIS-related worsening
of coinfections typically occurs within the first 6 months
of therapy, is associated with localized tissue inflammation
and low CD4 counts, and is most often observed in limited-
resource settings [41, 47]. Although T-cell restoration and
activation have been suggested as causing KS progression in
these patients, no direct link has been demonstrated [47].
Innate immune dysfunction (e.g., macrophage-activation)
has also been offered as an explanation for progressive KS
during cART, whereby the interaction of restored T-cell
populations with existing activated macrophages leads to
increased IRIS [19].
5. Conclusions
Kaposi’s sarcoma (KS) is a major cancer that still occurs in
HIV positive patients despite immune-restorative combined
antiretroviral therapy (cART). In this study we isolated HIV
from tumor and nontumor tissue sites frompatients who died
with KS which had metastasized to the viscera (KS1–KS3).
KS1 andKS2 died fromotherAIDS-associated complications,
whereas KS3 died directly due to a highly aggressive KS that
metastasized to lungs and caused death within 1 month of
initial KS diagnosis.We compared the HIV sequences among
patient’s tissue sites and found that KS1 and KS2 had unique
HIV in tumors compared to nontumor sites, whereas HIV
was freelymigrating among all tissues inKS3.While the study
is based on a very small sample size, the results suggest that
an HIV-associated mechanism may promote the metastatic
process in aggressive KS. It is also important to note that it
is unclear how the other AIDS-associated cancers may have
impacted the study (e.g., lymphoma in KS1 and BCBL in
KS2). Continued studies of the evolutionary patterns within
and among KS tumors could help in understanding the
mechanisms of metastasis as well as describing an additional
HIV reservoir during cART. Evolutionary studies of HIV in
tumor tissues are sorely lacking, and further investigation
could provide additional clarity into themechanisms of HIV-
associated cancers.
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